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Polymerase chain reactionAbstract Introduction: Hepatitis B surface antigen (HBsAg) is usually regarded as a marker of
hepatitis B virus (HBV) infection. The concurrence of lupus nephritis (LN) and HBsAg-positivity
is a challenge for the clinician, since immunosuppressant use may be associated with an increase
in viral replication and an exacerbation of liver disease.
Case presentation: Here, we describe the case of a 30-year-old Mexican woman with newly diag-
nosed focal proliferative LN who also tested repeatedly positive for HBsAg by chemiluminescent
microparticle immunoassay (CMIA). She had no clinical features of hepatitis and her liver function
tests were within normal limits. Her abdominal ultrasound was also normal. While waiting for fur-
ther results, she was started on lamivudine (100 mg daily). However, total HBV core antibody test
was negative. Owing to the infrequency of this serological pattern, an in vitro polymerase chain
reaction (PCR) assay was performed and HBV was not detected. Overall, we interpreted these
results as a false-positive screening. Methylprednisolone pulse therapy was subsequently given
(1 g daily for three doses) without hepatic repercussion, neither clinically nor biochemically.
Conclusions: Isolated HBsAg positivity may result from multiple causes, one of which is cross-
reactivity. To the best of our knowledge, this is the first report of a false-positive reading using
CMIA technique in an active lupus patient. It is reasonable to stress that lupus patients with a pos-
itive screening for HBV should undergo a confirmatory assay (such as genomic detection), since this
diagnosis may have important therapeutic implications.
 2016 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).itos s/n,
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Systemic lupus erythematosus (SLE) is a multisystem autoim-
mune disorder which commonly affects renal function. Its eti-
ology is currently elusive [1]. SLE is characterized by B
lymphocyte hyperactivity and autoantibodies against nuclear
self-antigens. This condition has a worldwide distribution
and predominantly affects women [2]. The prevalence of SLE
in the Mexican population has been reported to be 0.6%. Mex-
ican lupus patients tend to have a more severe disease, a lower
age of onset than European women and a higher frequency of
flares [3,4]. Pregnancy in women with SLE is a significant chal-
lenge and the Mexican clinical practice guidelines for the man-
agement of such cases integrate the best available evidence for
the treatment and follow-up [5].
Hepatitis B and C are among the most important
transfusion-transmitted infections and sources of liver diseases
worldwide. In Mexico, the prevalence reports of these viruses
are scarce and the overall rates were mentioned to be 0.72%
(0.63–0.76%) for hepatitis C virus (HCV) and 0.11% (0.08–
0.14%) for hepatitis B surface antigen (HBsAg) [6]. The asso-
ciation between chronic HCV infection and SLE may occur.
HCV antibodies and active viremia were reported in 20.4%
and 8.2% of Egyptian lupus patients, respectively [7]. This fre-
quency differs from one population to another and the preva-
lence of antibodies against HCV and hepatitis B virus (HBV)
in SLE was not higher than in the Mexican general population
[8]. Genetic factors play a crucial role in the development of
chronic liver disease from HBV infection. In Mexico, there is
predominance of genotype H while in Central and South
America it is genotype F. Both genotypes appear to be linked
to a benign course of disease in contrast to other genotypes in
Caucasians that are common in acute and chronic HBV infec-
tions. Hepatocellular carcinoma is rare in Mexicans, but it has
been associated with genotype F1b among Argentineans [9].
The relationship between SLE and HBV remains incom-
pletely understood. It could be assumed that these patients have
a higher prevalence of HBV infection. However, it is compara-
ble with the general population. HBsAg is usually regarded as a
marker of HBV infection [1]. Although this is not the case in
Mexico, it is not uncommon to find elsewhere patients with
lupus nephritis (LN) who also tested positive for HBsAg
[8,10]. This concurrence is a challenge for the clinician, since
immunosuppressant use may be associated with an increase
in viral replication and an exacerbation of liver disease [10].
Here, we describe the case of a young woman with LN who
tested repeatedly positive for HBsAg, which was later inter-
preted as a false-positive reaction, and received methylpred-
nisolone pulse therapy with no hepatic repercussion, neither
clinically nor biochemically.
2. Case report
A 30-year-old woman presented to the clinic with 8-months of
malaise, alopecia, unexplained weight loss and symmetric pol-
yarthralgia. She also reported one episode of fever three days
prior to this visit but denied rashes, photosensitivity, and
naso-oral ulcers. She had been taking oral contraceptives for
one year, reported having had five sexual partners to date,Please cite this article in press as: Delgado-Garcı´a G et al. Isolated HBsAg positivity
matologist (2016), http://dx.doi.org/10.1016/j.ejr.2016.02.007and inconsistent condom use. She took no regular medication,
had not received blood transfusion or vaccination against
HBV, and had never been hospitalized before, except for one
brief stay for labor and delivery about a year and a half ago,
when she was diagnosed with pregnancy-induced hyperten-
sion. There were no maternal or fetal complications during this
period, and her child is currently healthy, even though she did
not breastfeed him.
On physical examination her ankles, wrists and metacar-
pophalangeal joints were bilaterally tender and swollen. Areas
of alopecia were also noted. Laboratory investigation was
notable for microcytic anemia (8.7 g/dL) and lymphopenia
(658 cells/lL). This evaluation also revealed a serum creatinine
of 1.0 mg/dL with blood urea nitrogen of 23 mg/dL, and
1414 mg of proteins in spot urine sample. 20 erythrocytes per
high power field (hpf) and 5 leukocytes/hpf were found by
urine microscopy. She had hypoalbuminemia (2.3 g/dL) but
all other liver function tests (LFTs) were within normal limits
(aspartate transaminase 17 IU/L and alanine transaminase
12 IU/L).
She was then admitted for further evaluation and manage-
ment. The diagnosis of SLE was made briefly after her admis-
sion [11] and her SLE disease activity index (SLEDAI-2K)
score was 22 [12]. She also met criteria for lupus nephritis
[13]. The patient therefore underwent a kidney biopsy, which
was consistent with focal proliferative lupus nephritis (Class
III [A]) according to the International Society of Nephrol-
ogy/Renal Pathology Society (ISN/RPS) [14], and was started
on oral prednisone (30 mg daily), an angiotensin converting
enzyme (ACE) inhibitor, hydroxychloroquine (300 mg nightly)
and atorvastatin.
The following serological tests were found to be positive in
our patient: antinuclear antibodies (1:2560, speckled pattern),
anti-double-stranded deoxyribonucleic acid (dsDNA) antibod-
ies (1:1280), and anti-Smith antibodies (77.1 U/mL). She had
also hypocomplementemia (C3 37 mg/dL, C4 4.24 mg/dL).
Upon her admission, she was offered a screening for HBV
(ARCHITECT HBsAg Qualitative II assay, Abbott, Illinois),
and she accepted it. Our therapeutic strategy was restrained
by this result, since HBsAg test was found to be reactive
(2.20 sample/cutoff [S/CO] ratio). She had no clinical features
of hepatitis and her LFTs were within normal limits. Abdom-
inal ultrasound was also normal.
While waiting for further results (11 days in total), she was
started on lamivudine (100 mg daily). HBV screening was
repeated and she tested reactive again (1.85 S/CO). However,
total HBV core antibody (anti-HBc) test (ARCHITECT
Anti-HBc II assay, Abbott, Illinois) was negative (<1.00 S/
CO). Owing to the infrequency of this serological pattern, an
in vitro polymerase chain reaction (PCR) assay (RealTime
HBV, Abbott, Illinois) was performed and HBV was not
detected. Overall, we interpreted these results as a false-
positive screening and, in the following days, methylpred-
nisolone pulse therapy (1 g daily for three doses) was given.
This induction had no hepatic repercussion, neither clinically
nor biochemically. In conjunction with the patient, we decided
to administer intravenous cyclophosphamide in the outpatient
setting. However, she did not attend for follow up. During her
hospital stay, the patient provided informed consent to report
her case.in a Mexican patient with newly diagnosed lupus nephritis, The Egyptian Rheu-
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An interplay between SLE and HBV has been formerly
pointed out [10]. In our country and abroad, the prevalence
of HVB infection is not comparatively higher in lupus patients
[8,15]. It has been suggested that, in these patients, their
immune response could account for this unexpected prevalence
and that IFN-amay have a role in this latter response [15]. The
differential diagnosis between LN and HBV-related nephropa-
thy is difficult due to the common clinical features as well as
other extrahepatic manifestations [15]. However, in these
cases, a correct diagnosis is essential because therapeutic
options are quite different.
Although in our patient the diagnostic and therapeutic
management was restricted by financial constraint, her clinical
picture and paraclinical results lead us to consider that repeat-
edly positive HBsAg did not actually reflect an HBV infection,
but a false-positive reading. We used chemiluminescent
microparticle immunoassay (CMIA) as a screening test for
HBV infection and, when it tested reactive, we repeated it as
suggested by the manufacturer, but at this threshold ratio (S/
CO < 100) its positive predictive value is quite limited
(27.3%). Therefore, also following the manufacturer’s recom-
mendations, a confirmatory test was performed [16]. We did
not perform a neutralization assay, but we extended our diag-
nostic scope by including anti-HBc and PCR. CMIA was also
used for determining anti-HBc; this test has a very high speci-
ficity (>99%) [17]. Furthermore, the PCR that we used has a
specificity of 100% [18]. While waiting for further results, our
patient was started on lamivudine because of its rapid
and potent antiviral effect [10,19]. This drug has been
used in LN patients with HBV infection [10], as well as in those
with rapidly progressive glomerulonephritis secondary to HBV
[20].
Isolated HBsAg positivity may result from multiple
causes. The hypothesis of primary acute infection seems unli-
kely, considering the PCR detection sensitivity. Anti-HBc
negativity is also quite significant since, in these cases, the
probability of acute infection in HBsAg positive cases is nil.
Our patient had not been previously vaccinated, also ruling
out this hypothesis. In our patient, isolated HBsAg positivity
could be explained by cross-reactivity [21]. At first glance, our
finding (a false-positive HBsAg in a patient with LN) may
appear to lack novelty or maybe it could be interpreted as
textbook knowledge, something that everyone knows. Never-
theless, this is the first report of a false-positive reading using
this technique (CMIA) in an active lupus patient. In previous
cases other techniques were used [22], which are no longer in
use today. As discussed before, most of weakly positive
HBsAg results can be falsely positive [21]. In regions with
low prevalence of HBV infection, as in our country [23], most
cases of isolated HBsAg positivity can be linked to nonspeci-
fic reactivity since true reactivity has not been confirmed by
neutralization test or genomic detection [21]. Cross-
reactivity has also been described in biopsy tissue of patients
with LN, even in those without serological evidence of HBV
infection [1].
In conclusion, it is reasonable to stress that lupus patients
with a positive screening for HBV should undergo a confirma-
tory assay (such as genomic detection), since this diagnosis
may have important therapeutic implications.Please cite this article in press as: Delgado-Garcı´a G et al. Isolated HBsAg positivity
matologist (2016), http://dx.doi.org/10.1016/j.ejr.2016.02.007Conflict of interest
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